A detailed history of Creative Planning transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Creative Planning holds 25,409 shares of ARWR stock, worth $498,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,409
Previous 28,276 10.14%
Holding current value
$498,778
Previous $734,000 33.11%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$19.36 - $29.54 $55,505 - $84,691
-2,867 Reduced 10.14%
25,409 $491,000
Q2 2024

Aug 15, 2024

BUY
$21.87 - $28.24 $52,925 - $68,340
2,420 Added 9.36%
28,276 $734,000
Q1 2024

May 10, 2024

BUY
$27.21 - $39.48 $202,850 - $294,323
7,455 Added 40.51%
25,856 $739,000
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $26,775 - $39,190
1,263 Added 7.37%
18,401 $563,000
Q3 2023

Nov 16, 2023

SELL
$26.2 - $36.08 $24,863 - $34,239
-949 Reduced 5.25%
17,138 $460,000
Q2 2023

Jul 21, 2023

BUY
$25.16 - $41.38 $93,393 - $153,602
3,712 Added 25.82%
18,087 $644,000
Q1 2023

May 15, 2023

SELL
$23.68 - $38.51 $23,182 - $37,701
-979 Reduced 6.38%
14,375 $365,000
Q4 2022

Feb 10, 2023

BUY
$28.0 - $40.56 $21,308 - $30,866
761 Added 5.21%
15,354 $622,000
Q3 2022

Nov 03, 2022

BUY
$29.63 - $48.31 $22,222 - $36,232
750 Added 5.42%
14,593 $482,000
Q2 2022

Aug 15, 2022

BUY
$27.79 - $50.61 $33,542 - $61,086
1,207 Added 9.55%
13,843 $487,000
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $2,297 - $4,058
58 Added 0.46%
12,636 $581,000
Q4 2021

Feb 11, 2022

SELL
$58.09 - $82.51 $43,277 - $61,469
-745 Reduced 5.59%
12,578 $834,000
Q3 2021

Nov 10, 2021

BUY
$58.38 - $84.96 $43,785 - $63,719
750 Added 5.97%
13,323 $832,000
Q2 2021

Aug 04, 2021

BUY
$62.15 - $90.32 $203,354 - $295,527
3,272 Added 35.18%
12,573 $1.04 Million
Q1 2021

Apr 30, 2021

BUY
$61.35 - $90.47 $38,773 - $57,177
632 Added 7.29%
9,301 $617,000
Q4 2020

Jan 29, 2021

BUY
$43.82 - $85.37 $13,847 - $26,976
316 Added 3.78%
8,669 $665,000
Q2 2020

Jul 23, 2020

SELL
$26.12 - $43.27 $60,546 - $100,299
-2,318 Reduced 21.72%
8,353 $361,000
Q1 2020

May 05, 2020

SELL
$20.56 - $63.12 $39,166 - $120,243
-1,905 Reduced 15.15%
10,671 $307,000
Q4 2019

Jan 30, 2020

SELL
$28.14 - $73.01 $12,972 - $33,657
-461 Reduced 3.54%
12,576 $798,000
Q3 2019

Nov 01, 2019

SELL
$26.26 - $34.86 $12,210 - $16,209
-465 Reduced 3.44%
13,037 $367,000
Q2 2019

Jul 26, 2019

BUY
$17.43 - $28.82 $47,671 - $78,822
2,735 Added 25.4%
13,502 $358,000
Q1 2019

Apr 24, 2019

SELL
$12.05 - $20.18 $122,428 - $205,028
-10,160 Reduced 48.55%
10,767 $198,000
Q4 2018

Feb 01, 2019

BUY
$10.74 - $19.7 $224,755 - $412,261
20,927 New
20,927 $260,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.